Author(s): Alfaro, Tiago ; Froes, Filipe ; Vicente, Cláudia ; Costa, Rui ; Gavina, Cristina ; Baptista, Rui ; Maio, António ; da Cunha, Saraiva ; Neves, João Sérgio ; Leuschner, Pedro ; Duque, Sofia ; Pinto, Paula
Date: 2025
Persistent ID: http://hdl.handle.net/10400.5/98317
Origin: Repositório da Universidade de Lisboa
Subject(s): Respiratory syncytial virus; Chronic conditions; Older people; Recommendations; Vaccination
Background: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection, hospitalisation and death in adults. Methods: Based on evidence regarding the impact of RSV on adult populations at risk for severe infection and the efficacy and safety of RSV vaccines, the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine endorses this position paper with recommendations to prevent RSV-associated disease and its complications in adults through vaccination. Conclusion: The RSV vaccine is recommended for people aged ≥50 years with risk factors (chronic obstructive pulmonary disease, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, and residence in a nursing home) and all persons aged ≥60 years. If it cannot be made available to this population, then the vaccine should be prioritised for individuals aged ≥75 years and those aged ≥50 years with risk factors. The vaccine should preferably be given between September and November and can be co-administered with the influenza vaccine. Ongoing studies on RSV vaccines may justify extending these recommendations in the future.
